Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Authors
Keywords
-
Journal
Nature Reviews Rheumatology
Volume 18, Issue 11, Pages 641-656
Publisher
Springer Science and Business Media LLC
Online
2022-10-06
DOI
10.1038/s41584-022-00841-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metabolic adaptation of lymphocytes in immunity and disease
- (2022) Nicole M. Chapman et al. IMMUNITY
- T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
- (2022) Alexander X. Lozano et al. NATURE MEDICINE
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion
- (2022) Sonam Ansel et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
- (2022) Nilasha Ghosh et al. Journal for ImmunoTherapy of Cancer
- Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
- (2022) Marcus Wölffer et al. Cancers
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
- (2022) Yared Hailemichael et al. CANCER CELL
- IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy
- (2022) Julie Delyon et al. CANCER CELL
- Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
- (2022) Sang T. Kim et al. Nature Communications
- Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
- (2022) Akshay J. Patel et al. Nature Communications
- Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology
- (2021) Sabrina Hoa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease
- (2021) Monique K. van der Kooij et al. ANNALS OF INTERNAL MEDICINE
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- TNF in the era of immune checkpoint inhibitors: friend or foe?
- (2021) Allen Y. Chen et al. Nature Reviews Rheumatology
- Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
- (2021) Donghui Wang et al. Frontiers in Oncology
- The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases
- (2021) Chunlan Wu et al. Immunotherapy
- Inflammatory markers in autoimmunity induced by checkpoint inhibitors
- (2021) Beate Husain et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience
- (2021) Vineel Bhatlapenumarthi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
- (2021) Maria Grigoriou et al. Cancer Immunology Research
- Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
- (2021) Lauren J Brown et al. Journal for ImmunoTherapy of Cancer
- Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors
- (2021) Karl H. Tully et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- 1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
- (2021) J.S. Weber et al. ANNALS OF ONCOLOGY
- Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series
- (2021) Corrado Campochiaro et al. European Journal of Internal Medicine
- Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
- (2021) Robin Reschke et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases
- (2021) Cynthia Yeung et al. JOURNAL OF IMMUNOTHERAPY
- Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
- (2021) Miles C. Andrews et al. NATURE MEDICINE
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- (2021) Julie R Brahmer et al. Journal for ImmunoTherapy of Cancer
- Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study
- (2021) Geoffroy Bilger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
- (2021) Marion Panhaleux et al. EUROPEAN JOURNAL OF CANCER
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
- (2021) Jedd D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
- (2021) Luis G. Paz-Ares et al. Journal of Thoracic Oncology
- Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors
- (2021) Nicholas Gulati et al. Cancer Medicine
- Humoral and cellular correlates of a novel immune-related adverse event and its treatment
- (2021) Amrit S Gonugunta et al. Journal for ImmunoTherapy of Cancer
- First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
- (2021) M. Reck et al. ESMO Open
- Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry
- (2020) Rik J. Verheijden et al. CLINICAL CANCER RESEARCH
- Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis
- (2020) Elizaveta Efuni et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
- (2020) Kyung Hwan Kim et al. OncoImmunology
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
- (2020) Marie Kostine et al. ANNALS OF THE RHEUMATIC DISEASES
- The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study
- (2020) Jean-Marie Michot et al. EUROPEAN JOURNAL OF CANCER
- Elevated levels of IL‑17A and IL‑35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non‑small cell lung cancer
- (2020) Yi Wang et al. Oncology Letters
- Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
- (2020) Nieves Martinez Chanza et al. Journal for ImmunoTherapy of Cancer
- Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
- (2020) J. Haanen et al. ANNALS OF ONCOLOGY
- Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
- (2020) Adrienne M. Luoma et al. CELL
- Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
- (2020) Yi-Te Huang et al. Frontiers in Neurology
- Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy
- (2020) William Murray-Brown et al. Journal for ImmunoTherapy of Cancer
- Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
- (2020) Andressa S Laino et al. Journal for ImmunoTherapy of Cancer
- Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
- (2020) Katerina Chatzidionysiou et al. CLINICAL RHEUMATOLOGY
- Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
- (2020) Yohann Loriot et al. EUROPEAN JOURNAL OF CANCER
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
- (2020) David M. Waterhouse et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
- (2020) Ying Jing et al. Nature Communications
- Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
- (2020) Weilei Hu et al. iScience
- Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
- (2020) Syed Hussaini et al. CANCER TREATMENT REVIEWS
- Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
- (2020) Anne Montfort et al. CLINICAL CANCER RESEARCH
- Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
- (2019) Alessio Cortellini et al. ONCOLOGIST
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- (2019) Celeste Lebbé et al. JOURNAL OF CLINICAL ONCOLOGY
- Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management
- (2019) Diederik De Cock et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
- (2019) Elisabeth Perez-Ruiz et al. NATURE
- Anti‐PD‐1 Immunotherapy‐Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer
- (2019) Christopher S. Nabel et al. ONCOLOGIST
- Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
- (2019) Blake M. Warner et al. ONCOLOGIST
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma
- (2019) Candice Lesage et al. JOURNAL OF IMMUNOTHERAPY
- A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
- (2019) Jarushka Naidoo et al. Journal of the National Comprehensive Cancer Network
- Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
- (2019) Laura C. Kennedy et al. Journal of the National Comprehensive Cancer Network
- Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches
- (2019) Sharda Yadav et al. BIOSENSORS & BIOELECTRONICS
- Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
- (2019) T. Sakakida et al. Clinical & Translational Oncology
- Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases
- (2019) Chuan Huang et al. JOURNAL OF AUTOIMMUNITY
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis
- (2019) Takahiro Yamada et al. INTERNAL MEDICINE
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
- (2019) Guillaume Manson et al. Journal for ImmunoTherapy of Cancer
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
- (2018) Katharina C. Kähler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Rheumatic paraneoplastic syndromes – A clinical link between malignancy and autoimmunity
- (2018) Bernhard Manger et al. CLINICAL IMMUNOLOGY
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Early B cell changes predict autoimmunity following combination immune checkpoint blockade
- (2018) Rituparna Das et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- B cells in the pathogenesis of primary Sjögren syndrome
- (2018) Gaëtane Nocturne et al. Nature Reviews Rheumatology
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
- (2018) Michael D. Richter et al. Arthritis & Rheumatology
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
- (2018) Yinghong Wang et al. Journal for ImmunoTherapy of Cancer
- Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
- (2018) Andrew L Mammen et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Rheumatic immune-related adverse events from cancer immunotherapy
- (2018) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- Immune dysregulation in cancer patients developing immune-related adverse events
- (2018) Shaheen Khan et al. BRITISH JOURNAL OF CANCER
- PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
- (2018) Laure Hirsch et al. BRITISH JOURNAL OF CANCER
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
- (2018) Su Y. Lim et al. CLINICAL CANCER RESEARCH
- Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series
- (2018) Emma L. Mitchell et al. EUROPEAN JOURNAL OF CANCER
- Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
- (2018) Omar Hasan Ali et al. EUROPEAN JOURNAL OF CANCER
- Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs
- (2018) Arianna Draghi et al. INTERNATIONAL JOURNAL OF CANCER
- Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis
- (2018) Laura C Cappelli et al. RHEUMATOLOGY
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
- (2017) Ralf Gutzmer et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- (2017) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- (2017) Paul M Ridker et al. LANCET
- Malignancy and the Risks of Biologic Therapies
- (2017) Raphaèle Seror et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
- (2017) Franck Carbonnel et al. Seminars in Immunopathology
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors
- (2017) Heinz Läubli et al. OncoImmunology
- Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma
- (2016) N Matsumura et al. ACTA DERMATO-VENEREOLOGICA
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
- (2016) B. Lee et al. ANNALS OF ONCOLOGY
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- (2016) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease
- (2016) Lara V. Maul et al. JOURNAL OF IMMUNOTHERAPY
- Mechanism of action of methotrexate in rheumatoid arthritis and the search for biomarkers
- (2016) Philip M. Brown et al. Nature Reviews Rheumatology
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
- (2016) Sumit K. Subudhi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- (2014) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma
- (2014) Pia Moinzadeh et al. ARTHRITIS RESEARCH & THERAPY
- Optimized glucocorticoid therapy: Teaching old drugs new tricks
- (2013) Cindy Strehl et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
- (2013) C. G. Joseph et al. SCIENCE
- Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry
- (2012) Lene Dreyer et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy
- (2012) Maria A. Lopez-Olivo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
- (2011) X. Mariette et al. ANNALS OF THE RHEUMATIC DISEASES
- Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
- (2010) Thomas F Gajewski et al. CURRENT OPINION IN IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started